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Lung disease is a major cause of death in the United
States, with current therapeutic approaches serving
only to manage symptoms. The most common
chronic and life-threatening genetic disease of the
lung is cystic fibrosis (CF) caused by mutations in
the cystic fibrosis transmembrane regulator (CFTR).
We have generated induced pluripotent stem cells
(iPSCs) from CF patients carrying a homozygous
deletion of F508 in the CFTR gene, which results in
defective processing of CFTR to the cell membrane.
This mutation was precisely corrected using CRISPR
to target corrective sequences to the endogenous
CFTR genomic locus, in combination with a com-
pletely excisable selection system, which signifi-
cantly improved the efficiency of this correction.
The corrected iPSCs were subsequently differenti-
ated to mature airway epithelial cells where recovery
of normal CFTR expression and function was de-
monstrated. This isogenic iPSC-based model sys-
tem for CF could be adapted for the development
of new therapeutic approaches.
INTRODUCTION
In cystic fibrosis (CF), a thick sticky mucus forms in the lungs
impairing breathing and providing a rich environment for patho-
gens to flourish, leading to premature respiratory failure. It
affects multiple organ systems leading to problems in the liver,
pancreas, and small bowel. There has been a substantial in-
crease in the knowledge of molecular and cellular mechanisms
over the last two decades, which has translated to improvement
in care and an increase in the average life expectancy from 14
years in 1980 to 37 years in 2012. The disease still severely im-
pacts the quality of life with a significant shortening of life expec-
tancy. Therefore, development of new therapeutic approaches is
critical in the absence of a potential cure. The underlying cause,Cell Remutations in the cystic fibrosis transmembrane regulator (CFTR)
gene, prevents the expression or function of this chloride trans-
porter at the cell membrane (Rogan et al., 2011). Studying the
disease has proven difficult due to the shortcomings of animal
models. In the mouse CFTR knockout model, for example, an
upregulation of calcium-activated chloride channels is sufficient
to overcome the lack of functional CFTR (Boyd and Porteous,
2004). More recently, ferret and pig models of CF have been
generated and thought to more closely replicate the human
form of the disease (Rogers et al., 2008; Sun et al., 2010; Welsh
et al., 2009). Studying the human disease still remains a chal-
lenge. There is a lack of availability of primary lung tissues and
tissues from deceased CF patient lungs are inherently variable
due to the differences in chronic infection and treatment
regimens.
The ability to generate pluripotent stem cells from accessible
tissues, such as skin, has opened the door for modeling human
disease in a dish, increasing the potential for understanding the
mechanisms of disease, testing novel therapeutic approaches,
and developing cell therapies in a human system (Takahashi
et al., 2007a, 2007b). Induced pluripotent stem cells (iPSCs),
together with the recent explosion in genome-editing technolo-
gies, enable unprecedented capacity for patient-specific dis-
ease modeling, correction, and therapy. The latest tool in
genome editing is called clustered, regularly interspaced, short
palindromic repeats (CRISPR)-associated (Cas) systems, which
is found naturally in the adaptive immune system of bacteria and
archaea (Hale et al., 2012; Millen et al., 2012; Wiedenheft et al.,
2012). The CRISPR system is essentially comprised of a ribo-
nucleoprotein endonuclease, Cas9, that can catalyze double-
strand cleavage of DNA in a sequence-specific manner defined
by a guide RNA (gRNA) element complementary to the target
DNA sequence. This simple two-component gene-targeting sys-
tem has been co-opted for broader use by engineering synthetic
gRNA hairpins to replace the bipartite bacterial RNA element (Ji-
nek et al., 2012) and codon optimizing the bacterial Cas9 protein
for optimized expression in higher eukaryotes (Cong et al., 2013;
Mali et al., 2013). Recent work has shown that the CRISPR/Cas9
system can be used for efficient andmultiplexed genome editing
in a broad range of organisms, including bacteria (Jiang et al.,ports 12, 1385–1390, September 1, 2015 ª2015 The Authors 1385
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Figure 1. Footprint-free CRISPR-Mediated
Correction of CF iPSCs
(A) Schematic of strategy used for CRISPR-medi-
ated correction of the CFTR DF508 mutation. Red
triangle denotes the DF508 deletion (shown in red
in the sequence at the bottom) and green triangles
denote the correction of the deleted triplet of ba-
ses. The TTAA pBac recognition site is underlined.
The actual CFTR target sequence is shown below
with the gRNA target sequence in blue and the
PAM in green.
(B) Sequencing analysis of the endogenous CFTR
gene at the genomic locus of the DF508 mutation
from wild-type and CF patient-derived iPSCs. The
position of the CTT deletion in the mutant iPSCs as
compared to the wild-type is indicated by the red
box and arrow.
(C) Integration-specific PCR of puromycin-resis-
tant single-cell clones of CF iPSCs after CRISPR
treatment. Indicated clones contain the integrated
selection cassette and corrective sequence in the
correct position at the CFTR genomic locus.
(D) Screening by ClaI digest of a single-cell cor-
rected clone after excision and negative selection
of unexcised clones by ganciclovir. Indicated
clones show precise and complete excision of the
selection cassette from the endogenous CFTR
genomic locus, leaving behind only the corrected
F508 sequence and the intended silent mutations
encoding the restrictions sites used for screening
here.
(E) Sequencing analysis of corrected, excised
clone shows the corrected DF508 mutation and
adjacent silent mutations introduced in the
endogenous CFTR gene.
(F) Excision screening was done with different
variations of the pBac transposase.2013), mice (Wang et al., 2013), zebrafish (Hwang et al., 2013),
yeast (DiCarlo et al., 2013), Xenopus tropicalis (Nakayama
et al., 2013), and human cells (Cho et al., 2013; Cong et al.,
2013;Mali et al., 2013). The capability of Cas9 tomediate precise
double-stranded breaks (DSBs) in the DNA genome opens the
door to an infinite range of genome engineering possibilities.
RESULTS
Derivation of CF iPSCs and Strategy for GeneCorrection
of CFTR DF508
We obtained a skin biopsy from a CF patient organ donor;
we isolated and expanded fibroblasts for reprogramming. The
iPSCs were generated either by using a six-factor polycistronic
lentivirus followed by successful excision using Cre-RNA (Firth
et al., 2014) or by using four individual factor Sendai virus (Fusaki
et al., 2009). All iPSC lines generated retained all the hallmarks of
pluripotent stem cells (Figure S1). To correct the causative
DF508 mutation in the patient-derived CF iPSCs, we developed
a customized CRISPR system consisting of two components as
follows: (1) a plasmid encoding the full-length Cas9 protein,
codon optimized for optimal expression in human cells and1386 Cell Reports 12, 1385–1390, September 1, 2015 ª2015 The Audriven by the stem cell-compatible eukaryotic transcription elon-
gation factor 1 alpha 1 (EEF1A1) promoter; and (2) a separate
plasmid containing a U6 promoter-driven gRNA hairpin cassette.
The gRNA cassette was designed so that we could clone unique
guide sequences into the RNA hairpin by using specifically de-
signed primers containing the desired target guide sequences
and PCR cloning into the vector backbone. The gRNAs were de-
signed to target sequences in the vicinity of the DF508 mutation
in the endogenous CFTR gene (Figure 1A). The patient-derived
fibroblasts and iPSCs were confirmed to be homozygous for
the phenylalanine deletion at position 508 (DF508) (Figure 1B).
The functional activity of these gRNAs, in combination with our
customized CRISPR system, was validated in HEK293T cells
and in CF iPSCs by Surveyor assay (Figure S2A).
For targeting the DF508 mutation at its endogenous genomic
locus, a donor vector was developed in order to achieve efficient,
footprint-free correction of the CFTR gene (Figure 1A). The vec-
tor includes an EEF1A1 promoter-driven GFP-Puro-TK cassette
flanked with recognition sites for the piggyBac transposase
along with the homology arms with the corrected CFTR seq-
uence for integration into the endogenous genomic locus.
Upon successful CRISPR-mediated integration into the genomicthors
target site, we can select for integration using puromycin and
then seamlessly excise the selection cassette by expressing
the pBac transposase (System Biosciences). This excision
should proceed without leaving behind any genomic footprint
from the donor vector other than the desired correction of the
target DF508 mutation, as it uses a suitably placed TTAA pBac
recognition site that occurs naturally within the target genomic
sequence, as outlined in Figure 1A. We can then select against
unexcised colonies in a subsequent round of clonal selection us-
ing ganciclovir sensitivity of clones expressing the unexcised
thymidine kinase (TK) gene.
CRISPR-Mediated Gene Targeting of Endogenous CFTR
in CF iPSCs
The Cas9 vector, CFTR gRNA vector, donor vector, and/or GFP
were co-nucleofected in various combinations into CF iPSCs.
Then, 48 hr after plating at a single-cell density, the colonies
were treated with puromycin and the surviving colonies were
selected and analyzed. The CFTR locus-specific segment of
DNA was amplified using an integration-specific primer pair,
with one primer contained within the selection cassette and
the other outside the homology arm of the donor vector (Fig-
ure 1C). PCR products arising from clones screened with this
combination of primers, spanning the junction between the
target and insert, indicate that these puromycin-resistant clones
contain the integrated selection cassette and corrective se-
quences in the correct location and orientation. Of the 36 clones
picked and analyzed, six were positive for correct integration, at
an overall efficiency of 16.7%. The sequence of the integration-
specific product at the correct target locus in at least one allele of
the endogenous CFTR gene in each of the positive clones was
confirmed by sequencing.
Complete Excision of SelectionMarkers Using piggyBac
Transposase
The selection cassette was subsequently excised using the pig-
gyBac transposase system, which allows removal of the pBac
site-flanked sequence without leaving behind any genomic
footprint at the target site. Three variations of the piggyBac
transposase (wild-type, integration-specific Super PiggyBac,
or an excision-specific version from System Biosciences) were
nucleofected into one of the integration-positive iPSC clones,
to compare their relative efficiencies at excising the integrated
cassette. The genomic DNA for each of the ganciclovir-resistant
iPSC colonies was analyzed by PCR amplification of the CFTR
locus and ClaI restriction enzyme digest of the amplicon (Fig-
ure 1D). The donor plasmid contained a silent mutation to intro-
duce aClaI site in close vicinity of the correction site. A number of
corrected, excised clones were isolated, with nearly 90% effi-
ciency when we used the excision-specific pBac transposase.
A summary of excision experiments is provided in Figure 1F.
Analysis of Off-Target Effects of Genome-Editing
Approach
Corrected, excised clones were verified by sequencing (Fig-
ure 1E) and one particular clone was then analyzed in detail for
off-target effects of CRISPR by whole-exome sequencing. We
compared observedmutations to predicted off-target sites usingCell Rethe CRISPR design tool (http://crispr.mit.edu/; Cong et al.,
2013). No mutations (single nucleotide variants [SNVs], inser-
tions and deletions) occurred within 300 bp of a predicted off-
target site. After filtering, the predominant type of mutation
was SNVs (80%) with the remainder being insertions and dele-
tions at roughly the same proportion (Figure S2B). With regard
to the length of these observed insertions and deletions, a heavy
skew was observed to lengths that were <3 nt (Figure S2C).
Given the type of mutations, short length of insertions and dele-
tions, and lack of predicted off-target events, the acquiredmuta-
tions were not due to the correction technology itself. Table S2
lists all the observed mutations derived from the whole-exome
sequencing data. PCR analysis of genomic DNA of corrected
clones, both before and after excision and using primers specific
to the selection cassette, was negative, indicating there was no
random integration of the selection cassette elsewhere in the
genome (data not shown).
Recovery of CFTR Function in Airway Epithelial Cells
Derived from iPSCs
Differentiation to proximal airway epithelial cells was carried out
as previously described (Firth et al., 2014). Briefly, our mutant
and gene-corrected CF iPSC lines were differentiated through
definitive endoderm (DE), anterior foregut endoderm (AFE), and
NKX2.1 lung progenitors, and were matured in an air-liquid inter-
face. All iPSC lines were capable of generating DE, as shown in
Figure 2A by FOXA2 staining, and maturing to lung epithelial
cells with tight junctions after 48 days of differentiation, as indi-
cated by ZO-1 staining occludin (red) in the lower images of Fig-
ure 2A. The qPCR analysis of key genes representing different
stages of lung differentiation is shown in Figure 2B for wild-
type, CF-mutant, and CF-corrected iPSCs. DE markers Fork-
head box A2 (FOXA2), GATA-binding protein 6 (GATA6), and
sex-determining region Y box 17 (SOX17) all increased by day
5 of differentiation. NK2 homeobox 1 (NKX2.1), one of the ear-
liest transcription factors specifying lung, increased over the dif-
ferentiation time course, as did club cell 10-kDa protein (CC10,
club cells), keratin 5 (KRT5) and tumor protein 63 (TP63) (basal
cells), Mucin 5AC (MUC5AC, goblet cells), and CFTR (functional
epithelial cells).
We isolated epithelial cell adhesion molecule (EPCAM)-posi-
tive cells at day 48 of differentiation for analysis ofCFTR currents
by whole-cell patch clamp methods. In the mutant differentiated
cells, no increase in CFTR chloride current was observed in
response to a cocktail of forskolin, genistein, and isobutylmethyl
xanthine (IBMX). In the CRISPR gene-corrected epithelial cells,
half of the cells stably patched responded to stimulation, similar
to our observations in wild-type iPSC-derived lung epithelial
cells (Firth et al., 2014). The increase in current was blocked by
specific CFTR inhibitor CFTRinh-172 (Figure 2C). Additionally,
CFTR undergoes N-glycosylation, enabling conformational
changes essential to its translocation to the cell membrane.
CFTR contains two glycosylation sites that can be detected by
gel electrophoresis of the protein. Core glycosylation produced
a band of 150 kDa (band A) and complex glycosylation pro-
duced a band of 170 kDa (band B); DF508 mutant CFTR is un-
able to be glycosylated and only band A can be detected (Patrick
et al., 2011). Thewestern blot in Figure 2D shows the presence ofports 12, 1385–1390, September 1, 2015 ª2015 The Authors 1387
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Figure 2. Generation of Functional Respiratory Epithelial Cells from CF Mutant and Gene-Corrected iPSCs
(A) Representative images show CF-corrected and CF-mutant iPSC differentiation to DE (day 5) with DAPI (blue) and FOXA2 (cyan). Scale bars, 100 mm (white)
and 20 mm (yellow).
(B) The mRNA expression of DE, AFE, and lung epithelial cell markers over the time course of differentiation for wild-type, CF-mutant, and CF-corrected iPSCs.
Data are corrected for internal controls and normalized to wild-type iPSC cDNA (mean ± SEM, n = 6–15 from a minimum of three experimental replicates).
(C) Averaged current/voltage plots for baseline (blue), in presence of forskolin, genistein, and IBMX (pink) and with the addition of CFTRinh-172 (green). Data
represented are mean ± SEM for zero of four patched mutant cells and three of eight patched gene-corrected cells. (Bottom) Representative current traces from
one gene-corrected differentiated epithelial cell at baseline and in the presence of FSK cocktail and CFTRinh-172 (left to right); traces represent 20-mV in-
crements from 80 to +80 mV.
(D) Western blot showing the presence of the membrane translocated and glycosylated protein in the wild-type and gene corrected cells (band B) and the
unglycoslylated CFTR band in all three cell lines (band A). WT, wild-type; M, mutant; C, gene corrected.the un-glycosylated and glycosylated bands in differentiated
wild-type and gene-corrected iPSCs, but only the un-glycosy-
lated band in the differentiated CF-mutant iPSCs.
DISCUSSION
While genomic correction of CF patient iPSCs recently has been
demonstrated using zinc-finger nucleases (ZFNs) (Crane et al.,
2015), this report now describes correction of iPSCs derived
from a CF patient carrying the most commonly found homozy-
gous DF508 mutation using CRISPR. CRISPR also recently has
been used to correct CFTR in adult intestinal stem cells; how-
ever, these cells cannot be utilized to study the pathophysiology
of CF in the lung (Schwank et al., 2013). Our footprint-free
CRISPR-based approach is able to address some of the tech-
nical limitations regarding the persistence of a single LoxP site1388 Cell Reports 12, 1385–1390, September 1, 2015 ª2015 The Auafter CRE excision of the donor sequence and the use of inte-
grating vector to generate the iPSCs (Crane et al., 2015), thus
providing amore optimal approachwhen considering clinical ap-
plications. In addition, we observe a much-improved efficiency
of genomic correction using our selection-based methodology
with CRISPR, while completely eliminating any local genomic
footprint in the endogenous CFTR gene.
Having such a footprint-free approach to gene editing has
enabled us to precisely and efficiently edit a point mutation in
the genome while leaving no genomic scar in patient cells. It is
hoped that eventually this approach could be utilized as a cell
therapy approach for patients with lung disease. A more imme-
diate use for such cells would be for their utilization in research
and drug development. Further refinement of the differentiation
protocol will lead to effective in vitro isogenic models of human
lung diseases like CF, which can be used to study mechanismsthors
of disease, screen for novel therapeutic approaches, and even
clinically to identify responders to currently available therapeutic
options.
EXPERIMENTAL PROCEDURES
Tissue used in this study was donated by organ donors/cadavers and Institu-
tional Review Board exception was granted.
Nucleofection of iPSCs
Adherent cells were dissociated using Tryple (Gibco), centrifuged, and resus-
pended in TeSR containing 10 mM ROCK inhibitor, Y27632. Cells (1 3 106)
were resuspended in 100 ml Lonza Nucleofection solution (according to the
manufacturer’s protocol). The following amounts of DNA were added: 2 mg
Cas9, 2 mg gRNA, 5 mg PBHR, 2 mg pmaxGFP, and/or 2.5 mg PiggyBac Trans-
posase in the required experimental combination. The samples were then
nucleofected using the B-16 protocol on the device. After nucleofection,
TeSRwas added and cells transferred to a six-well Matrigel-coated plate. After
24–48 hr of incubation, the nucleofected iPSCs were split onto 10-cm mouse
embryonic fibroblast (MEF) plates at single-cell density for colony screening or
harvested for genomic DNA analysis.
Colony Isolation and Screening
After puromycin (1 mg/ml) or ganciclovir (3 mg/ml) treatment, colonies were me-
chanically passaged into a matrigel-coated 12-well plate in TeSR with ROCK
inhibitor. Once the isolated iPSC clones were grown to the appropriate size,
each well was split into duplicate 12-well matrigel plates. The cells were disso-
ciated using trypsin, centrifuged at 1,000 rpm for 5 min, and resuspended in
1ml TeSR with ROCK inhibitor. Two-thirds of each cell suspension was added
to a matrigel plate for genomic DNA isolation, while the other third was carried
to another matrigel plate designated for clonal maintenance and expansion.
Genomic DNA was isolated as described in the Supplemental Experimental
Procedures. To screen genomic DNA samples for integration of the correc-
tive/selective sequences, theCFTR target locuswas amplified by PCR, to yield
an integration-specific product using one primer within the selection cassette
and one outside the homology arm in the genomic sequence upstream of
the integration site (F: CTTCCTCTGCTACCTCCTTTCC, R: CCGATAAAACA
CATGCGTCA). For screening excised colonies, PCR products were digested
with ClaI, a silent restriction site that was introduced via the targeting vector, at
37C in an incubator for at least 1 hr. Digests were run on a 1%agarose gel and
excised clones were identified by the presence of cleavage products of the ex-
pected sizes.
PiggyBac Transposase Nucleofection: Excision
Excision of the integrated selection cassette from corrected clones was done
by overexpressing piggyBac transposase in clonal iPSC lines expressing pu-
romycin resistance and sensitivity to ganciclovir. Various piggyBac transpo-
sase vectors (4 mg, SystemBiosciences) were nucleofected into 13 106 iPSCs
using the Amaxa Nucleofector Device as described above, followed by selec-
tion with 3 mg/ml ganciclovir to eliminate unexcised cells.
Differentiation to Respiratory Epithelial Cells
Differentiation was carried out as previously described (Firth et al., 2014).
Briefly, transwell inserts were coated with a combination of fibronectin
(50 mg/ml), laminin (5 mg/ml), and collagen IV (60 mg/ml, Sigma-Aldrich). A sin-
gle-cell suspension of iPSC was generated using Accutase. Then, 300,000
iPSCs were plated per 30-mm insert in TeSR with ROCK inhibitor for 24 hr. Dif-
ferentiation to airway epithelial cells proceeded with media changes as
detailed in Firth et al. (2014). Data were analyzed at day 42 of differentiation
(day 28 of ALI). Methodology for immunofluorescence imaging is included
in the Supplemental Experimental Procedures and antibodies are listed in
Table S2.
Analysis of the Epithelial Differentiation
Immunocytochemistry was carried out on paraffin-embossed sections as
previously detailed (Firth et al., 2014). RNA was isolated using the QIAGENCell ReRNeasy kit as per themanufacturer’s instructions and 500 ng RNAwas reverse
transcribed using a high-capacity cDNA kit (Applied Biosciences) as previ-
ously described (Firth et al., 2014). Real-time qPCR was carried out on the
7900HT Fast Real-Time PCR System in the Salk Functional Genomics Core fa-
cility, and data were analyzed using SDS2.3 and Microsoft Excel. Data are ex-
pressed as relative expression (ct) corrected for internal control GAPDH and
normalized to iPSC ± SEM.
Western Blot
Protein was isolated from the samples using RIPA buffer with protease inhib-
itors for 30 min on ice. Protein lysate (40 mg) was loaded onto a 4%–12% Bis-
Tris gel (Life Technologies) and run in MOPS buffer (Life Technologies). Protein
was transferred to a nitrocellulose membrane Themembrane was probed with
mouse anti-human CFTR-570 (1:1,000) and anti-human b-actin (1:5,000).
Patch-Clamp Electrophysiology
Patch-clamp experiments were carried out as previously described (Firth et al.,
2014). Briefly, the pipette (intracellular) solution contained the following (in
mM): NaCl (5), MgCl2 (2), CsCl (145), EGTA (10), HEPES (10), MgATP (5), and
CsOH (to pH 7.2). The bath (extracellular) solution contained the following (in
mM): CaCl2 (2), NaCl (150), MgCl2 (2), HEPES (10), and Tris HCl (to pH 7.4).
Cells were held at a holding potential of 40 mV and 200-ms depolarizing
steps in 20-mV increments from 80 to +80 mV were applied. The data
were filtered at 3.3 kHz and digitized at 4 kHz. Cm and Rs were routinely
compensated for. Pipette resistance was 2–4MOhm. ForCFTR activation, for-
skolin (10 mM), IBMX (100 mM), and genistein (50 mM) were added to the extra-
cellular solution, and the cells were perfused for 5 min prior to recording. After
CFTR activation, cells were perfused with CFTR-inh172 (3-[(3-trifluoromethyl)
phenyl]-5-[(4-carboxyphenyl)methylene]-2-thioxo-4-thiazolidinone,10 mM) for
5 min prior to recording.
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